Silgan (SLGN) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for May 27, 2025, to elect three directors, ratify the auditor, and hold a say-on-pay vote.
Record date for voting is April 4, 2025, with 106,993,180 shares outstanding, each entitled to one vote.
Quorum requires a majority of outstanding shares; broker discretionary voting is not allowed for director elections or say-on-pay.
Proxy materials and annual report are available online; shareholders can revoke proxies at any time before the meeting.
Voting matters and shareholder proposals
Election of three Class I directors to serve until 2028.
Ratification of Ernst & Young LLP as independent auditor for fiscal year 2025.
Advisory vote to approve executive compensation (say-on-pay).
No other substantive business or shareholder proposals are planned for the meeting.
Board of directors and corporate governance
Board expanded from eight to nine members; three standing committees: Audit, Compensation, and Nominating.
All committee members are independent as per NYSE standards.
Board leadership is separated between Chairperson and CEO.
Board and committees met regularly in 2024; all directors attended at least 75% of meetings.
Corporate Governance Guidelines and Code of Business Conduct and Ethics are in place and available online.
Retirement policy restricts director nominations for those reaching age 75 during their term, with exceptions for nominees under the Stockholders Agreement.
Latest events from Silgan
- Record 2025 growth in key segments, with further earnings and cash flow gains expected in 2026.SLGN
Q4 20254 Feb 2026 - €838M acquisition expands dispensing leadership, targets €20M synergies and 10% EPS accretion.SLGN
M&A Announcement3 Feb 2026 - Q2 net sales fell 3.2% to $1.38B, but gross margin and adjusted EPS both increased.SLGN
Q2 20242 Feb 2026 - Q3 2024 saw record dispensing growth and Weener acquisition, setting up strong 2025 prospects.SLGN
Q3 202417 Jan 2026 - Record Q4 results and 2025 double-digit growth outlook driven by acquisitions and dispensing demand.SLGN
Q4 20249 Jan 2026 - Record Q1 2025 sales and earnings growth driven by Weener acquisition and volume gains.SLGN
Q1 202524 Dec 2025 - Record Q2 sales, 15% EPS growth, and strong outlook despite $20M EBIT headwinds.SLGN
Q2 202516 Nov 2025 - Q3 sales up 15.1% to $2.01B, with strong pet food and fragrance, but Q4 faces volume headwinds.SLGN
Q3 20255 Nov 2025